PROCEPT BioRobotics (PRCT) Misses Q4 EPS by 21c, Offers Guidance

PROCEPT BioRobotics Corporation (NASDAQ: PRCT) reported Q4 EPS of ($0.53), $0.21 worse than the analyst estimate of ($0.32). Revenue for the quarter came in at $76.1 million versus the consensus estimate of $93.77 million.

GUIDANCE:

PROCEPT BioRobotics Corporation sees FY2026 revenue of $390-410 million, versus the consensus of $422 million.

For earnings history and earnings-related data on PROCEPT BioRobotics Corporation (PRCT) click here.

You May Also Be Interested In

• Occidental Petroleum releases Q2 2026 earnings considerations
• Men’s Wearhouse owner Tailored Brands, bankrupt in 2020, files for IPO
• Apple suing OpenAI over alleged misappropriation of trade secrets